
    
      The proposed trail will be use a double-blind, placebo-controlled design to conduct the first
      randomized controlled trial of the COMT inhibitor, tolcapone, in nicotine dependent women.
      This study will determine if tolcapone is superior to placebo by attenuation the severity of
      nicotine withdrawal and smoking urges during short-term abstinence. Withdrawal severity will
      be assessed by a self-report scale and cognitive assessment, including a sustained-attention
      task. Smoking urges will be assessed by a self-report scale.
    
  